MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial -

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers | Skin disorders
Summary
RCT (n=1391) found that an antigen-specific immunotherapeutic alone was not efficacious in this clinical setting (median disease-free survival 11·months in MAGE-A3 group and 11.2 months) placebo group, thus development of MAGE-A3 in melanoma has been stopped.
UKMi comment

A commentary discusses what can be concluded based on the negative results of the DERMA trial, as well as a negative MAGE-A3 trial in lung cancer and suggests that they will be considered as a milestone to start a different road for cancer immunotherapeutics.
Related links: Comment